Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of L19-IL2 plus stereotactic ablative radiotherapy in metastatic non-small cell lung cancer
NL-OMON56015Phase 2Completed
- Sponsor
- Maastricht University
- Start
- Jan 2020
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darleukin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Maastricht University. Primary endpoint: Progression-free survival. Started Jan 2020; status: completed.
02
Drugs
darleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56015.